Syndivia to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025

STRASBOURG, France, April 25, 2025 – Syndivia, a leading biotechnology company focused on the development of next-generation antibody-drug conjugates (ADCs), today announced it will present preclinical data on its clinical asset SDV2102 at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25–30, 2025 in Chicago, Illinois.

The presentation will highlight SDV2102, a first-in-class DAR1 ADC targeting PSMA, built using Syndivia’s proprietary GeminiMab linker platform. The data demonstrate an unprecedented therapeutic index, supporting the potential of SDV2102 as a safer and more effective therapy for metastatic castration-resistant prostate cancer (mCRPC).

Presentation Details:
Poster Title: Preclinical evaluation of SDV2102, a novel PSMA-targeting DAR1 ADC for mCRPC treatment
Poster Number: 2249
Session Category: Experimental and Molecular Therapeutics
Session Title: Antireceptors and Other Biological Therapeutic Agents
Session Start: 4/27/2025 2PM
Session End: 4/27/2025 5PM